CIK 0000882796 · Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 621413174
- Phone
- 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- 4 Open-market buy Director bought 7,861 shares at $6.36 ($49,996)
- 4 Open-market buy Director bought 2,500 shares at $6.40 ($16,000)
- 4 Open-market buy Director bought 5,000 shares at $6.38 ($31,900)
- 4 Open-market buy Director bought 15,000 shares at $6.25 ($93,750)
- 4 Open-market buy Chief Financial Officer bought 36,300 shares at $5.57 ($202,191)
- 4 Open-market buy Chief R&D Officer bought 30,000 shares at $5.86 ($175,800)
- 4 Open-market buy Director bought 21,940 shares at $5.49 ($120,451)
- 4 Open-market buy Chief Legal Officer bought 5,000 shares at $5.53 ($27,650)
- 4 Open-market buy President & CEO bought 30,000 shares at $5.55 ($166,500)
- 4 Open-market buy Chief Commercial Officer bought 30,000 shares at $5.47 ($164,100)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Regulation FD disclosure
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Shares withheld for taxes Chief R&D Officer gave up 7,525 shares (to pay taxes)
- 4 Grant or award Director acquired 999 shares (grant or award)
- 4 Grant or award Director acquired 999 shares (grant or award)
- S-3ASR Offering Registration Statement
- 10-K Report Annual Report
Page 11 of 99 · 1,967 filings